- Meeting abstract
- Open Access
Effect of orally administered moxaverine on ocular haemodynamics
© Palkovits et al; licensee BioMed Central Ltd. 2011
- Published: 5 September 2011
- Diabetic Retinopathy
- Macular Degeneration
- Optic Nerve Head
- Color Doppler Image
Reduced ocular perfusion is related to several common eye diseases, like age-related macular degeneration, diabetic retinopathy or glaucoma. Moxaverine, a phosphodiesterase inhibitor, has a vasodilating effect on peripheral vessels and is therefore clinically used to increase blood flow. It was recently shown that a dose of 150 mg moxaverine administered intravenously increases retinal blood flow in healthy subjects and in patients with ocular diseases. The aim of this study was to investigate the effect of oral moxaverine on ocular blood flow.
Sixteen healthy subjects were included in this randomized, double-blinded, placebo-controlled, two-way crossover study and two study days were scheduled. The subjects were randomized to receive either 900 mg moxaverine (p.o. in three equal doses at two-hour intervals) or placebo on the first study day. On the second study day the subjects were crossed over to the alternative treatment. Ocular haemodynamics were measured at baseline and 5 hours after the study drug administration. A Laser Doppler Flowmeter was used to measure the choroidal and optic nerve head blood flow. The blood velocities in the retrobulbar vessels were assessed using the Color Doppler Imaging.
No difference was found in the haemodynamic parameters (choroidal, optic nerve head and retrobulbar blood flow) between moxaverine and placebo group. The p values for the choroidal and optic nerve head blood flow were p = 0.52 and p = 0.54, respectively. Similarly, the values assessed with the Color Doppler Imaging also showed no significant difference. Additionally, moxaverine had no effect on choroidal, optic nerve head and retrobulbar blood flow.
Our results show that orally administered moxaverine, in contrast to intravenous moxaverine, does not alter the ocular blood flow. This may be related to the low bioavailability of moxaverine after oral administration.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.